Evidence map›Paper›PMID 35117630›Full record

ArticleTranslational cancer research2020

Metallothionein 1M (MT1M) inhibits lung adenocarcinoma cell viability, migration, and expression of cell mobility-related proteins through MDM2/p53/MT1M signaling.

Wei Xu, Guo-Jun Jiang, Guo-Zhen Shi, Ming-Zhi Chen, Tie-Liang Ma, Yong-Fei Tan

Abstract read
In one paragraph

Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Harnessing the TAF1 Acetyltransferase for Targeted Acetylation of the Tumor Suppressor p53.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wei XuDepartment of Cardiothoracic Surgery, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
Guo-Jun JiangDepartment of Cardiothoracic Surgery, Yixing People's Hospital, Yixing, Wuxi 215004, China.
Guo-Zhen ShiDepartment of Cardiothoracic Surgery, Yixing People's Hospital, Yixing, Wuxi 215004, China.
Ming-Zhi ChenDepartment of Cardiothoracic Surgery, Yixing People's Hospital, Yixing, Wuxi 215004, China.
Tie-Liang MaDepartment of Cardiothoracic Surgery, Yixing People's Hospital, Yixing, Wuxi 215004, China.
Yong-Fei TanDepartment of Cardiothoracic Surgery, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetallothionein 1M (MT1M) functions to regulate cell proliferation and cancer metastasis. This study assessed the effects of MT1M overexpression and mouse double minute 2 homolog (MDM2) knockdown on the regulation of non-small cell lung cancer A549 cell viability, migration, and protein expression

methodsA549 cells were stably infected with lentivirus carrying MT1M cDNA or transiently transfected MDM2 siRNA and/or treated with the p53 inhibitor for the assessment of changes in cell viability, wound healing, Transwell migration, and qRT-PCR and Western blot assays. Luciferase reporter assay was performed to investigate p53 binding to the MT1M promoter.

resultsThe data showed that MT1M overexpression inhibited A549 cell viability and migration capacity

conclusionsIn conclusion, MDM2 can bind to and phosphorylate p53 protein to inactivate the protein, thereby reducing MT1M expression and leading to tumor cell proliferation and migration.

Indexed as

Metallothionein 1M (MT1M)migrationmouse double minute 2 homolog (MDM2)p53proliferation

Identifiers

PMID35117630
PMCPMC8798298

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.